Eurofins Scientific recently enhanced its leadership in biopharmaceutical services and expanded its Contract Development and Manufacturing (CDMO) offering with several strategic acquisitions, including:
Alphora Research Inc. (Eurofins Alphora) is a premier, full-service contract research, development and manufacturing organization (CDMO) for complex and niche small molecule active pharmaceutical ingredients (APIs). Based in Mississauga, Ontario, Canada, with more than 145 employees and facilities totaling more than 5,500 m2, Alphora offers a full spectrum of complex API development, testing and manufacturing services, including extensive capabilities in multi-step syntheses, as well as the development of cytotoxic and highly potent APIs.
Advinus Therapeutics (Eurofins Advinus) is a leading preclinical contract research company for Safety Assessment, DMPK, and CMC services, offering end-to-end solutions in the areas of preclinical toxicology testing, API process development and scale up, analytical R&D, drug metabolism and pharmacokinetics, as well as long-term non-clinical toxicology testing, including carcinogenicity studies. The company also supports early clinical development through multi kilo scale API synthesis under cGMP. With over 25 years of GLP compliance and certification, Eurofins Advinus has more than 380 staff and operates a state-of-the art 20,000 m2 facility in Bangalore, India.
Amatsigroup (Eurofins Amatsigroup) is one of the leading CDMOs in Europe providing high-quality, customized drug development solutions for specialty and biopharma clients, including bioprocess development, biomanufacturing, analytical studies, formulation development and manufacturing (Fill & Finish capacities) of clinical or small commercial batches, as well as complementary services such as preclinical studies, bioanalysis and clinical trial supply. GLP & GMP certified, Eurofins Amatsigroup employs 400 staff and operates eight sites in France, two sites in Belgium and one site in the US, totaling more than 28,000 m2.
With the addition of these acquisitions into Eurofins’ existing sterile and non-sterile manufacturing sites in the US and Europe, Eurofins is able to support biopharmaceutical companies from the preclinical phase through to commercialization of niche products; can address a wide array of development challenges with a full spectrum of complex drug substance and drug product development, testing and manufacturing services; and is well-positioned to support the growing R&D outsourcing needs throughout the North American, European and Asia-Pacific regions.
Visit our website to learn more about Eurofins’ recent CDMO acquisitions.